BioNTech (BNTX) Stock Forecast & Price Target

$108.20 +6.06 (+5.93%)

(As of 11/21/2024 ET)

BioNTech - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
4

Buy
12

Based on 16 Wall Street analysts who have issued ratings for BioNTech in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 4 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for BNTX.

Consensus Price Target

$138.79
28.27% Upside

According to the 16 analysts' twelve-month price targets for BioNTech, the average price target is $138.79. The highest price target for BNTX is $171.00, while the lowest price target for BNTX is $122.00. The average price target represents a forecasted upside of 28.27% from the current price of $108.20.

Get the Latest News and Ratings for BNTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioNTech and its competitors.

BNTX Analyst Ratings Over Time

Type	Current Forecast 11/23/23 to 11/22/24	1 Month Ago 10/24/23 to 10/23/24	3 Months Ago 8/25/23 to 8/24/24	1 Year Ago 11/23/22 to 11/23/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	8 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)
Hold	4 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$138.79	$135.54	$109.09	$153.69
Forecasted Upside	28.27% Upside	22.13% Upside	23.70% Upside	56.89% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

Central Bank Abandons USD (Ad)

You know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD!

Get Your FREE Gold Investor Kit NOW!

BNTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BioNTech Stock vs. The Competition

Type	BioNTech	Medical Companies	S&P 500
Consensus Rating Score	2.81	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	28.27% Upside	26,677.73% Upside	8.51% Upside
News Sentiment Rating	Neutral News See Recent BNTX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/19/2024	Berenberg Bank 2 of 5 stars	H. Gillis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$130.00	+27.61%
11/19/2024	Evercore ISI 2 of 5 stars	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	In-Line ➝ Outperform	$110.00 ➝ $125.00	+22.71%
11/18/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$150.00 ➝ $150.00	+50.42%
11/14/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$171.00 ➝ $171.00	+51.60%
11/8/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Shibutani Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$90.00 ➝ $137.00	+26.99%
11/5/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$132.00 ➝ $122.00	+10.28%
Democrats Sold Out the American Dream - Are you ready? (Ad) There's a massive housing crisis looming, and nobody on Main Street knows it yet... The Democrats sold out the American Dream - and now, millions of Americans are locked out of the housing market, forced to become "permanent renters." Click here to see exactly what you need to do >>>
11/4/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$125.00 ➝ $124.00	+10.95%
10/7/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$97.00 ➝ $136.00	+10.88%
9/24/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$93.00 ➝ $145.00	+28.26%
9/19/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$95.00 ➝ $150.00	+33.87%
9/18/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$97.00 ➝ $131.00	+5.04%
9/17/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$96.00 ➝ $150.00	+21.49%
9/16/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$125.00 ➝ $150.00	+23.75%
8/2/2024	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/7/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$123.00 ➝ $122.00	+32.90%
1/5/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
5/17/2023	Redburn Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$165.00 ➝ $170.00	+60.98%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:17 AM ET.

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, November 6, 2024. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com.

BioNTech
Bull Case

Here are some ways that investors could benefit from investing in BioNTech SE:

BioNTech SE has been actively developing and commercializing immunotherapies for cancer and infectious diseases, showing potential for significant growth in the biotechnology sector.
Recent institutional inflows from notable hedge funds and financial institutions indicate confidence in the company's future prospects, which could positively impact its stock performance.
The company's strong financial position with a low debt-to-equity ratio of 0.01 and healthy quick and current ratios suggest stability and efficient management of resources.
Despite recent challenges in revenue and earnings, BioNTech SE's market capitalization of $29.37 billion and consistent investment from institutional investors highlight long-term growth potential.
Goldman Sachs Group Inc. significantly increased its position in BioNTech SE during the fourth quarter, signaling a positive outlook on the company's future performance.

BioNTech
Bear Case

Investors should be bearish about investing in BioNTech SE for these reasons:

The company has reported negative net margins and returns on equity, indicating potential financial challenges that could impact shareholder returns.
Analyst estimates for revenue have not been consistently met, suggesting possible volatility in the company's financial performance.
BioNTech SE's recent earnings per share (EPS) results have fallen short of consensus estimates, raising concerns about its ability to meet market expectations.
The company's revenue for the quarter was down 23.3% year-over-year, reflecting a decline in sales that may affect future profitability and investor confidence.
Harding Loevner LP's substantial investment in BioNTech SE during the fourth quarter could indicate a high level of risk associated with the company's stock, potentially leading to increased market volatility.

BNTX Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for BioNTech is $138.79, with a high forecast of $171.00 and a low forecast of $122.00.
: 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 4 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BNTX shares.
: According to analysts, BioNTech's stock has a predicted upside of 28.27% based on their 12-month stock forecasts.
: Over the previous 90 days, BioNTech's stock had 5 upgrades by analysts.
: BioNTech has been rated by research analysts at Bank of America, Berenberg Bank, Canaccord Genuity Group, Deutsche Bank Aktiengesellschaft, Evercore ISI, HC Wainwright, HSBC, Jefferies Financial Group, JPMorgan Chase & Co., Morgan Stanley, TD Cowen, The Goldman Sachs Group, and UBS Group in the past 90 days.
: Analysts like BioNTech more than other "medical" companies. The consensus rating score for BioNTech is 2.81 while the average consensus rating score for "medical" companies is 2.80. Learn more on how BNTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Democrats Sold Out the American Dream - Are you ready? (Ad)

There's a massive housing crisis looming, and nobody on Main Street knows it yet... The Democrats sold out the American Dream - and now, millions of Americans are locked out of the housing market, forced to become "permanent renters."

Click here to see exactly what you need to do >>>

This page (NASDAQ:BNTX) was last updated on 11/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNTech (BNTX) Stock Forecast & Price Target